Algeria vs Estonia: Access to anti-retroviral drugs, male
Algeria
68.0%
in 2024
Estonia
68.0%
in 2022
Algeria rank
73rd
Estonia rank
73rd
Access to anti-retroviral drugs, male over time
- Algeria
- Estonia
How they compare
Algeria currently reports 68.0% against 68.0% in Estonia, a difference of 0.0%.
The two have swapped places 4 times across 23 shared years of data; in 2000 it was Estonia ahead.
Algeria ranks 73rd and Estonia ranks 73rd of 141 countries.
Across the 3 decades both report, Algeria averaged higher in 2 and Estonia in 1.
Head to head by decade
| Decade | Algeria | Estonia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 13.3% | 9.7% | 3.6% | Algeria |
| 2010s | 42.6% | 53.6% | 11.0% | Estonia |
| 2020s | 69.7% | 68.3% | 1.3% | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Algeria or Estonia?
- Algeria, at 68.0% against 68.0% in Estonia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Algeria and Estonia?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Estonia?
- 23 years are reported by both, from 2000 to 2022.
- How do Algeria and Estonia rank globally for access to anti-retroviral drugs, male?
- Algeria ranks 73rd and Estonia ranks 73rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.